MA46713A - Forme posologique pharmaceutique orale liquide comprenant un antagoniste du récepteur h2 à l'histamine et un antiacide - Google Patents

Forme posologique pharmaceutique orale liquide comprenant un antagoniste du récepteur h2 à l'histamine et un antiacide

Info

Publication number
MA46713A
MA46713A MA046713A MA46713A MA46713A MA 46713 A MA46713 A MA 46713A MA 046713 A MA046713 A MA 046713A MA 46713 A MA46713 A MA 46713A MA 46713 A MA46713 A MA 46713A
Authority
MA
Morocco
Prior art keywords
antiacid
histamine
dosage form
receptor antagonist
pharmaceutical dosage
Prior art date
Application number
MA046713A
Other languages
English (en)
Inventor
Katarina Lindell
Salih Muhsin Muhammed
Carina Siversson
Original Assignee
Johnson & Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc filed Critical Johnson & Johnson Consumer Inc
Publication of MA46713A publication Critical patent/MA46713A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA046713A 2016-11-01 2017-10-30 Forme posologique pharmaceutique orale liquide comprenant un antagoniste du récepteur h2 à l'histamine et un antiacide MA46713A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1651441 2016-11-01

Publications (1)

Publication Number Publication Date
MA46713A true MA46713A (fr) 2019-09-11

Family

ID=60766008

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046713A MA46713A (fr) 2016-11-01 2017-10-30 Forme posologique pharmaceutique orale liquide comprenant un antagoniste du récepteur h2 à l'histamine et un antiacide

Country Status (9)

Country Link
US (1) US20200038376A1 (fr)
EP (1) EP3534880B1 (fr)
CN (1) CN109890368B (fr)
AU (1) AU2017353968B2 (fr)
CA (1) CA3042466A1 (fr)
DK (1) DK3534880T3 (fr)
MA (1) MA46713A (fr)
RU (1) RU2761346C2 (fr)
WO (1) WO2018083583A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020350A (zh) * 2018-04-27 2020-12-01 强生消费者公司 液体口服药物剂型
CA3112541A1 (fr) * 2018-10-18 2020-04-23 Johnson & Johnson Consumer Inc. Nouvelle forme posologique
AU2020353342A1 (en) * 2019-09-27 2022-05-19 Johnson & Johnson Consumer Inc. Gel-chewable dosage form

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
AU7218294A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-alginate combinations
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
GB2338896B (en) * 1998-07-02 2003-05-21 Reckitt & Colmann Prod Ltd Chewable Capsules
US6260735B1 (en) * 2000-05-12 2001-07-17 Colgate-Palmolive Company Uniform dispensing dual chamber sachet
EP1933815A2 (fr) * 2005-10-14 2008-06-25 Microdose Technologies Inc. Conditionnement pharmaceutique d'une combinaison posologique orale
WO2007102726A1 (fr) 2006-03-09 2007-09-13 World-Trade Import-Export, Wtie, Ag. Combinaison synergique d'inhibiteurs des récepteurs h2, de silicone inerte et d'un complexe d'aluminate d'hydroxymagnésium
MXPA06010972A (es) * 2006-09-25 2009-04-17 World Trade Imp Export Wtie Ag Proceso para estabilizacion de famotidina.
GB2494439A (en) * 2011-09-09 2013-03-13 Nova Bio Pharma Technologies Ltd 6-Mercaptopurine oral suspension for the treatment of acute lymphoblastic leukaemia
US20130287899A1 (en) * 2012-04-25 2013-10-31 Avid Health, Inc. Center-in-shell chewable compositions with functional components

Also Published As

Publication number Publication date
US20200038376A1 (en) 2020-02-06
WO2018083583A1 (fr) 2018-05-11
EP3534880A1 (fr) 2019-09-11
EP3534880B1 (fr) 2022-05-18
RU2761346C2 (ru) 2021-12-07
DK3534880T3 (da) 2022-07-25
AU2017353968A1 (en) 2019-05-02
RU2019116746A (ru) 2020-12-03
CA3042466A1 (fr) 2018-05-11
CN109890368A (zh) 2019-06-14
RU2019116746A3 (fr) 2021-01-29
CN109890368B (zh) 2021-12-21
AU2017353968B2 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
FR21C1057I2 (fr) Composition pharmaceutique stable à dose fixe comprenant de la mométasone et de l'olopatadine
MA48763A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
MA47679A (fr) Détection de dose et identification de médicament pour dispositif d'administration de médicament
MA41818A (fr) Timbre à micro-aiguilles pour administration d'un principe actif à la peau
JP2017514871A5 (fr)
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
MA46713A (fr) Forme posologique pharmaceutique orale liquide comprenant un antagoniste du récepteur h2 à l'histamine et un antiacide
WO2016110806A3 (fr) Régime posologique pour antagonistes de madcam
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA53375A (fr) Dispositifs d'administration pour l'administration de médicaments
MA47069A (fr) Formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires
EP3784214A4 (fr) Forme galénique pharmaceutique orale liquide
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA47074A (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
MA55033A (fr) Formulation d'anticorps thérapeutique
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
MA43758A (fr) Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
IL280083A (en) A pharmaceutical dosage form that can be administered orally and with a modified release
MA49822A (fr) Combinaison pharmaceutique comprenant du ponesimod
MA44286A (fr) Formulation pharmaceutique de cinéol et d'amoxicilline
MA49618A (fr) Inhibiteurs de la mpo destinés à être utilisés en médecine